We believe there are no limits to our thinking or what that thinking can accomplish.
Advances in the development of biocompatible fluorescent tracer agents that can be detected by a sensor placed on the skin are at the core of MediBeacon’s scalable medical technology platform. The solutions are being designed to be clinically practical, relevant and easily understood.
Real-time GFR measurement has the potential, if used effectively, to give doctors information that could help them fundamentally transform their understanding of kidney function in such a way that it could change the practice of nephrology, critical care medicine and beyond.
Transdermal GI permeability measurement has the potential to be a tool that could help doctors to evolve their understanding of mucosal healing in a way that can impact the proactive care of those with inflammatory bowel diseases and a range of other autoimmune disorders.
Improvements in ocular and surgical visualization are other possible future uses of the florescent tracer technology.
Our preclinical product enables researchers to measure renal function in a streamlined and accurate manner. Over 400 peer-reviewed and conference abstracts describe the ground breaking research in which the transdermal measured GFR technique has been used. Improvements in preclinical research techniques have the potential to reduce the time it takes to get lifesaving treatments and pharmaceuticals from ideation to commercialization.*
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.